Uxin Limited, China's leading used car retailer, announced a 74.9% year-over-year revenue increase to RMB1.15 billion in Q2 2026, driven by an 88.8% rise in retail vehicle sales volume. Despite strong sales growth, the company faced a gross margin decline to -0.7% and an operating loss of RMB151.9 million due to sharp used car price declines and accelerated inventory sales. Management expects improved gross margins above 6% and retail transaction volumes of 20,500 to 21,000 vehicles in Q3 as market conditions stabilize and operational efficiencies improve. The company also highlighted ongoing equity financing and expansion projects to support long-term growth.
Uxin Limited's Q2 2026 financial results provide context for consumer cyclical sector activity on Pluang. For readers following this sector, here is Pluang's market snapshot as of Sep 24, 2026 13:41 WIB: Of 112 priced US consumer cyclical stocks, 35 rose and 69 fell. Peloton Interactive Inc (PTON) traded at USD 4.79 with a 1-day change of -4.58%.
A newly created wallet withdrew about $9.93 million worth of cryptocurrency from Binance on September 24. The withdrawal consisted mainly of 814,020 Uniswap (UNI) tokens valued at $7.24 million, along with 2,382 Binance Coin (BNB) worth $1.85 million...
Traders expect the Federal Reserve to raise interest rates four times by June 2027, pushing the federal funds rate to between 4.75% and 5%. This outlook has driven U.S. Treasury yields to new highs, with the 20-year yield nearing 5.5% and the 10-year...
Bitcoin fell below $83,000 on September 24, dropping to $82,874.93 amid rising U.S. 10-year Treasury yields, which reached their highest level since 2007 at 5.11%. This increase in yields has added downward pressure on cryptocurrency prices, with Eth...
The European Central Bank (ECB) has highlighted that speeches and interviews by its policymakers can influence financial markets as much as formal policy decisions. This communication strategy impacts euro-area markets and is now reflected in Bitcoin...
Poolbeg Pharma announced that its POLB 001 TOPICAL clinical trial will proceed as planned following an interim safety review that recommended no changes to the study protocol. The trial, which tests POLB 001 as a preventative treatment for cytokine r...
